Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Share-based Compensation: 2011-2025

Historic Share-based Compensation for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $2.7 million.

  • Abeona Therapeutics' Share-based Compensation rose 49.06% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 64.46%. This contributed to the annual value of $6.6 million for FY2024, which is 39.01% up from last year.
  • Abeona Therapeutics' Share-based Compensation amounted to $2.7 million in Q3 2025, which was down 4.98% from $2.8 million recorded in Q2 2025.
  • Abeona Therapeutics' Share-based Compensation's 5-year high stood at $2.8 million during Q2 2025, with a 5-year trough of $632,000 in Q3 2022.
  • In the last 3 years, Abeona Therapeutics' Share-based Compensation had a median value of $1.6 million in 2023 and averaged $1.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 75.09% in 2022, then surged by 146.36% in 2023.
  • Over the past 5 years, Abeona Therapeutics' Share-based Compensation (Quarterly) stood at $2.0 million in 2021, then crashed by 58.37% to $833,000 in 2022, then surged by 81.75% to $1.5 million in 2023, then rose by 29.13% to $2.0 million in 2024, then soared by 49.06% to $2.7 million in 2025.
  • Its Share-based Compensation stands at $2.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.7 million for Q1 2025.